CSTL icon

Castle Biosciences

19.32 USD
+0.19
0.99%
At close Updated May 18, 4:00 PM EDT
Pre-market
After hours
19.32
0.00
0%
1 day
0.99%
5 days
1.95%
1 month
-23.21%
3 months
-42.62%
6 months
-42.41%
Year to date
-49.87%
1 year
17.8%
5 years
-67.19%
10 years
-9.72%
 

About: Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Employees: 942

0
Funds holding %
of 7,974 funds
0
Analysts bullish %
of 1 analysts
0
Positive news %
of 9 articles
Price charts implemented using Lightweight Charts™